There was good news in the treatment of advanced melanoma at the 2013 meeting of the European Cancer Congress in Amsterdam. A new analysis of data about patients who received the monoclonal antibody Ipilimumab shows some patients are living longer than ever before, as much as ten years. It appears that patients who live three years have a significant chance of living much longer according to Dr. Stephen Hodi, a melanoma expert at Boston's Dana-Farber Cancer Institute. He presented his findings in Amsterdam and was interviewed by Patient Power's Andrew Schorr as to what this means for patients.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…